GUT:器官衰竭与感染性坏死在坏死性胰腺炎中扮演的作用

2018-07-08 MedSci MedSci原创

在所有胰腺炎患者中,早期持续性器官衰竭被认为是导致死亡的最重要原因。本项研究调查了坏死性胰腺炎患者器官衰竭的时间(发作和持续时间)与死亡率之间的关系及其与感染性胰腺坏死的关系。

背景及目的
在所有胰腺炎患者中,早期持续性器官衰竭被认为是导致死亡的最重要原因。本项研究调查了坏死性胰腺炎患者器官衰竭的时间(发作和持续时间)与死亡率之间的关系及其与感染性胰腺坏死的关系。

方法
研究人员对来自21家医院的639例坏死性胰腺炎患者的前瞻性数据库进行了回顾性分析。评估了器官衰竭的发作,持续时间和类型(即呼吸,心血管和肾功能衰竭)及其与死亡率和感染性胰腺坏死的关系。

结果
在639例坏死性胰腺炎患者中有240例(38%)出现器官衰竭。持续性器官衰竭(即任何类型或组合)在第一周开始为51%,患者死亡率为42%,第二周器官衰竭为13%,死亡率为46%,第二周后为36%,死亡率为29%。持续性多器官衰竭持续<1周,1-2周,2-3周或长于3周的患者的死亡率分别为43%,38%,46%和52%(p = 0.68)。单独器官衰竭患者的死亡率高于器官衰竭和感染胰腺坏死患者(44% VS 29%,p = 0.04)。然而,当排除具有非常早期死亡率的患者(入院后10天内),患有或未患有感染性胰腺坏死的器官衰竭患者具有相似的死亡率(28%VS34%,p = 0.33)。

结论
在坏死性胰腺炎患者中,与持续性器官衰竭相比,早期持续性器官衰竭与死亡率增加无关,而持续性器官衰竭在疾病过程中会加剧疾病的发展。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655427, encodeId=2462165542e85, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Fri Aug 03 06:49:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362892, encodeId=b7641362892ae, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Jul 10 01:49:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330319, encodeId=976d3303195c, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon Jul 09 07:13:46 CST 2018, time=2018-07-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655427, encodeId=2462165542e85, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Fri Aug 03 06:49:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362892, encodeId=b7641362892ae, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Jul 10 01:49:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330319, encodeId=976d3303195c, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon Jul 09 07:13:46 CST 2018, time=2018-07-09, status=1, ipAttribution=)]
    2018-07-10 millore
  3. [GetPortalCommentsPageByObjectIdResponse(id=1655427, encodeId=2462165542e85, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Fri Aug 03 06:49:00 CST 2018, time=2018-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362892, encodeId=b7641362892ae, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Jul 10 01:49:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=330319, encodeId=976d3303195c, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Mon Jul 09 07:13:46 CST 2018, time=2018-07-09, status=1, ipAttribution=)]
    2018-07-09 张新亮1853311252142e2fm

    好文献学习了

    0